How Did this Happen?
For starters, get the notion out of your head that these Chinese and Indian manufacturers worked with teams of doctors to develop some new wonder drug, because that’s now what they did…at all. Essentially, all these manufacturers did was re-brand current erectile dysfunction medication, targeting women instead of men. It’s that easy. They didn’t just blindly repackage the medicine however, and assume that woman would buy it. They based their decision on a landmark Indian study.
The Study
An Indian research team conducted a study in which they separated women with sexual arousal problems into two groups. One group was given Viagra, the other a placebo. Over a period of time, the women given Viagra reported greater instances of sexual satisfaction than did the placebo group, which lead researchers to conclude that Viagra may play a significant role in treatment of female libido problems. Unfortunately, the United States Food and Drug Administration did not deem this study too credible, and has yet to approve Viagra as a safe treatment for female sexual enhancement. This study prompted United States researchers to begin their own trials of a medication called ‘Lybrido’
What is Lybrido?
Lybrido is a drug containing both testosterone and Viagra-like substances, administered to help cure female libido issues. The U.S. conducted a trial administering Lybrido to 200 women, and then examined the impact of the drug on sexual arousal. Though the results of the trial are still under analysis, one of the researchers described what they discovered has “very, very promising.” Regardless of whether a female libido drug hits the U.S. market, these studies provide an interesting and hopeful look at potential cures for a problem suffered by millions of women worldwide.
